Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multi-Protein Classifier for Ovarian Cancer Detection.

Skubitz AP, Boylan KL, Geschwind KA, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS.

Cancer Prev Res (Phila). 2019 Feb 1. pii: canprevres.0221.2018. doi: 10.1158/1940-6207.CAPR-18-0221. [Epub ahead of print]


Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Uppendahl LD, Felices M, Bendzick L, Ryan C, Kodal B, Hinderlie P, Boylan KLM, Skubitz APN, Miller JS, Geller MA.

Gynecol Oncol. 2019 Jan 15. pii: S0090-8258(19)30039-3. doi: 10.1016/j.ygyno.2019.01.006. [Epub ahead of print]


Development of a multiplexed giant magnetoresistive biosensor array prototype to quantify ovarian cancer biomarkers.

Klein T, Wang W, Yu L, Wu K, Boylan KLM, Vogel RI, Skubitz APN, Wang JP.

Biosens Bioelectron. 2019 Feb 1;126:301-307. doi: 10.1016/j.bios.2018.10.046. Epub 2018 Oct 23.


Evaluating the potential of residual Pap test fluid as a resource for the metaproteomic analysis of the cervical-vaginal microbiome.

Afiuni-Zadeh S, Boylan KLM, Jagtap PD, Griffin TJ, Rudney JD, Peterson ML, Skubitz APN.

Sci Rep. 2018 Jul 18;8(1):10868. doi: 10.1038/s41598-018-29092-4.


A multiplex platform for the identification of ovarian cancer biomarkers.

Boylan KLM, Geschwind K, Koopmeiners JS, Geller MA, Starr TK, Skubitz APN.

Clin Proteomics. 2017 Oct 10;14:34. doi: 10.1186/s12014-017-9169-6. eCollection 2017.


IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.

Felices M, Chu S, Kodal B, Bendzick L, Ryan C, Lenvik AJ, Boylan KLM, Wong HC, Skubitz APN, Miller JS, Geller MA.

Gynecol Oncol. 2017 Jun;145(3):453-461. doi: 10.1016/j.ygyno.2017.02.028. Epub 2017 Feb 22.


Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.

Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, Skubitz APN.

J Biol Chem. 2017 Apr 14;292(15):6339-6351. doi: 10.1074/jbc.M116.746859. Epub 2017 Feb 23.


The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate.

Boylan KL, Buchanan PC, Manion RD, Shukla DM, Braumberger K, Bruggemeyer C, Skubitz AP.

Oncotarget. 2017 Feb 7;8(6):9717-9738. doi: 10.18632/oncotarget.14206.


A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics.

Boylan KL, Afiuni-Zadeh S, Geller MA, Hickey K, Griffin TJ, Pambuccian SE, Skubitz AP.

Clin Proteomics. 2014 Jul 14;11(1):30. doi: 10.1186/1559-0275-11-30. eCollection 2014.


Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA.

Gynecol Oncol. 2013 Sep;130(3):579-87. doi: 10.1016/j.ygyno.2013.05.027. Epub 2013 May 27.


Isothermal vitrification methodology development for non-cryogenic storage of archival human sera.

Less R, Boylan KL, Skubitz AP, Aksan A.

Cryobiology. 2013 Apr;66(2):176-85. doi: 10.1016/j.cryobiol.2013.01.003. Epub 2013 Jan 24.


Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer.

Nikas JB, Boylan KL, Skubitz AP, Low WC.

Cancer Inform. 2011;10:233-47. doi: 10.4137/CIN.S8104. Epub 2011 Oct 3.


Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation.

Boylan KL, Misemer B, De Rycke MS, Andersen JD, Harrington KM, Kalloger SE, Gilks CB, Pambuccian SE, Skubitz AP.

Int J Mol Sci. 2011 Feb 22;12(2):1334-58. doi: 10.3390/ijms12021334.


Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

Andersen JD, Boylan KL, Jemmerson R, Geller MA, Misemer B, Harrington KM, Weivoda S, Witthuhn BA, Argenta P, Vogel RI, Skubitz AP.

J Ovarian Res. 2010 Sep 10;3:21. doi: 10.1186/1757-2215-3-21.


Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum.

Boylan KL, Andersen JD, Anderson LB, Higgins L, Skubitz AP.

Proteome Sci. 2010 Jun 14;8:31. doi: 10.1186/1477-5956-8-31.


Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis.

Andersen JD, Boylan KL, Xue FS, Anderson LB, Witthuhn BA, Markowski TW, Higgins L, Skubitz AP.

Electrophoresis. 2010 Jan;31(4):599-610. doi: 10.1002/elps.200900441.


S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.

DeRycke MS, Andersen JD, Harrington KM, Pambuccian SE, Kalloger SE, Boylan KL, Argenta PA, Skubitz AP.

Am J Clin Pathol. 2009 Dec;132(6):846-56. doi: 10.1309/AJCPTK87EMMIKPFS.


Motility screen identifies Drosophila IGF-II mRNA-binding protein--zipcode-binding protein acting in oogenesis and synaptogenesis.

Boylan KL, Mische S, Li M, Marqués G, Morin X, Chia W, Hays TS.

PLoS Genet. 2008 Feb;4(2):e36. doi: 10.1371/journal.pgen.0040036.


A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.

Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S, Kansas GS, Van Ness BG.

Cancer Res. 2007 May 1;67(9):4069-78.


Transport and Partitioning of CO(2) Fixed by Root Nodules of Ureide and Amide Producing Legumes.

Vance CP, Boylan KL, Maxwell CA, Heichel GH, Hardman LL.

Plant Physiol. 1985 Aug;78(4):774-8.


Supplemental Content

Loading ...
Support Center